- EMA Starts New Review of Risks with High-strength Estradiol-containing Creams
- FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
- FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%)
- First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC
- Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer [ELCC Press Release]
- PROs Were Consistent with the ITT Population Across PD-L1 Subgroups in Patients with Stage III NSCLC Receiving Durvalumab or Placebo
Articles: Melanomas
Lester J Layfield et al.
European Oncology & Haematology, 2014;10(1):58–61
Lester J Layfield et al.
Oncology & Hematology Review, 2014;10(1):21–4
Oncology & Hematology Review 2013;9(1):36–40.
Kenneth F Grossmann et al., Shelley Christiansen et al.
Oncology & Hematology Review 2013;9(2):132–7
Oncology & Hematology Review (US), 2012;8(2):100-5
Breno R Lima et al., Arun D Singh et al.
European Oncology & Haematology, 2012;8(2):101–4
Byron E Wright,MD, FACS et al., Armando E Giuliano, MD, FACS et al.
US Oncological Review, 2008;4(1):11-4
Michael P O’Connell et al., Ashani T Weeraratna et al.
US Oncological Review, 2008;4(1):64-7
Sanjiv S Agarwala et al.
European Oncological Disease, 2007;1(2):100-2
Sonata Saulyte Trakymien et al.
European Oncology & Haematology, 2011;7(1):76-80
Anirban De et al., Winston Rennie et al.
European Oncology, 2009;5(1):35-7
Bryan Burmeister et al.
Asia-Pacific Oncology & Haematology, 2008;1(1):60-2
Joseph J Bennett et al.
US Oncological Disease, 2006;1(1):16-9
Marc S Ernstoff et al.
US Oncology Review, 2005;1(1):1-4